Jiangxi Fushine Pharmaceutical Co., Ltd. was established in March 2002 and is headquartered in Jingdezhen, a historic city renowned for its fine porcelain. In December 2015, we were listed on the Shenzhen Stock Exchange ChiNext Board (Stock Code: 300497). Today, Fushine has total assets of nearly RMB 5 billion, with 8 manufacturing bases, 2 import & export companies, and 2 research institutes. We are recognized as a National High-Tech Enterprise, a National Specialized and Innovative “Little Giant” Enterprise, a Jiangxi Provincial Champion in Manufacturing, as well as a Provincial Innovative Pilot Enterprise and Outstanding Private Enterprise in Jiangxi Province. We have also established a Provincial Enterprise Technology Center, a Provincial Engineering Research Center, and a Provincial Technology Innovation Center.
Our core businesses focus on the research, development, manufacturing, and commercialization of anti-infective APIs and intermediates. Building on our technological expertise, we are also expanding into lithium battery electrolyte additives and the microbial protein sector through synthetic biology.
In the pharmaceutical sector, we are a leading global production base and major supplier of β-lactamase inhibitors, and one of the few enterprises in China with an end-to-end value chain for carbapenem and penem products—from starting materials to downstream APIs. Our key products, including sulbactam, tazobactam, and penem-series intermediates, rank among the top in the industry in both production capacity and market share.
In the new energy sector, our flagship vinylene carbonate (VC) electrolyte additive ranks among the industry leaders in shipment volume.
In the biotechnology sector, we are the first company in Asia to achieve ton-scale industrial production of filamentous fungal protein. We have also independently developed a new Fusarium venenatum strain, now protected by a national invention patent, demonstrating our position as a domestic leader with globally competitive technology.
Over more than two decades of dedicated growth, we have built a balanced presence across three major pillars—pharmaceutical manufacturing, new energy materials, and microbial protein innovation—laying a solid foundation for sustainable global development. We remain committed to advancing pharmaceutical manufacturing on a global scale, serving as a leading supplier of new energy materials, and setting the industry benchmark in microbial protein.